8-K: Onconetix Implements 1-for-85 Reverse Stock Split to Maintain Nasdaq Listing, Secures Short-Term Promissory Note

Onconetix, Inc. announced a 1-for-85 reverse stock split effective June 13, 2025, aimed at regaining Nasdaq minimum bid price compliance, and disclosed a new $147,058.82 promissory note with Keystone Capital Partners, LLC.

Summary

• Onconetix, Inc. stockholders approved a reverse stock split proposal at a special meeting on May 30, 2025.
• The Board of Directors subsequently approved a 1-for-85 reverse stock split, effective 12:01 a.m. Eastern Time on June 13, 2025.
• The reverse stock split is intended to enable the company to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share.
• Post-split, the number of outstanding common shares will decrease from approximately 44.4 million to approximately 521,863.
• No fractional shares will be issued; stockholders entitled to fractional shares will receive a cash payment based on the closing price on June 12, 2025.
• The company issued an unsecured promissory note to Keystone Capital Partners, LLC on June 5, 2025, with a principal amount of $147,058.82 and an original issue discount of $22,058.82, for a purchase price of $125,000.00.
• The note is due upon the earlier of sufficient proceeds from an Equity Line of Credit (ELOC) or March 5, 2026, and is subject to mandatory prepayment from future securities offerings.
• The promissory note is subordinate to existing debt obligations to Veru Inc. and other Senior Indebtedness, but senior to other unsecured debt.
• Overdue amounts on the note will incur a late charge of 15% per annum.

Sentiment

Score: 3

Explanation: The sentiment is moderately negative. While the company is taking steps to address its Nasdaq listing issue and secure short-term financing, the underlying reasons (low stock price, need for high-cost debt) indicate financial and market challenges. The reverse split is a corrective action for a negative situation, not a sign of strong performance.

Positives

• The company is actively addressing its Nasdaq listing compliance issue through the reverse stock split, which is a necessary step to maintain its public trading status.
• Securing a promissory note provides short-term capital, indicating continued access to financing, albeit with specific terms.

Negatives

• The necessity of a reverse stock split indicates that the company's stock price has fallen below Nasdaq's minimum bid price requirement, reflecting poor market performance.
• The promissory note carries an original issue discount and a high late charge of 15% per annum, suggesting less favorable financing terms.
• The note's subordination to existing debt obligations to Veru Inc. and other Senior Indebtedness places the new lender in a junior position, which can be a less attractive investment.

Risks

• The company's ability to regain and maintain compliance with Nasdaq's listing criteria is not guaranteed, and delisting could negatively impact the market for its securities.
• There is uncertainty regarding the timing and completion of a proposed transaction with Ocuvex Therapeutics, Inc. and any related financing, which could impact future strategic plans.
• The company faces risks in its ability to commercialize or monetize its products, such as Proclarix, and integrate acquired assets and commercial operations.
• Onconetix has a present need for capital to commercially launch Proclarix and maintain adequate working capital.
• Risks exist concerning the company's ability to attract, hire, and retain skilled personnel necessary for commercial operations.
• Failure to obtain and maintain necessary regulatory approvals for its products poses a significant risk.
• The company's ability to obtain and maintain intellectual property protection for its current products is a risk factor.
• Reliance on third parties, including manufacturers and logistics companies, introduces operational risks.
• General risks inherent in the development, regulatory approval, and commercialization of biotechnology products apply.

Future Outlook

The company anticipates the reverse stock split will enable it to regain and maintain compliance with Nasdaq's minimum bid price requirement. Forward-looking statements also mention the potential for a definitive agreement for a proposed transaction with Ocuvex Therapeutics, Inc. and related financing, as well as the company's ability to commercialize Proclarix, attract skilled personnel, obtain regulatory approvals, maintain intellectual property, and manage reliance on third parties.

Management Comments

• The company's stockholders approved the proposal to effect a reverse split at the 2025 special meeting of stockholders held on May 30, 2025.
• The Board of Directors approved a 1-for-85 reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m. Eastern Time on June 13, 2025.
• The reverse stock split is intended to enable the Company to regain compliance with the minimum bid price requirement of $1.00 per share of common stock for continued listing on The Nasdaq Capital Market.

Industry Context

Onconetix operates in the commercial-stage biotechnology sector, specifically focusing on mens health and oncology. The need for a reverse stock split to maintain Nasdaq listing is a common occurrence for smaller biotechnology companies that may experience significant stock price volatility or decline due to clinical trial results, regulatory hurdles, or market perception. The securing of a promissory note, while providing short-term liquidity, also highlights the capital-intensive nature of the biotechnology industry and the ongoing need for financing to support R&D, commercialization efforts, and operational expenses.

Comparison to Industry Standards

• The 1-for-85 reverse stock split ratio is relatively high compared to typical reverse splits, which often range from 1-for-2 to 1-for-20. This indicates a significant need to boost the per-share price to meet Nasdaq's minimum bid requirement, potentially reflecting a more severe stock price decline than many peers.
• The terms of the promissory note, including an original issue discount and a 15% late charge, suggest that Onconetix may be facing challenges in securing more favorable financing, which is not uncommon for smaller, commercial-stage biotech companies that may not yet be profitable or have consistent revenue streams, unlike larger, established pharmaceutical companies such as Pfizer or Johnson & Johnson.
• The company's focus on commercializing products like Proclarix (an in vitro diagnostic test for prostate cancer approved in the EU) and ENTADFI (FDA-approved for benign prostatic hyperplasia) positions it in a competitive market with established players like Exact Sciences (for cancer diagnostics) and various pharmaceutical companies offering BPH treatments. The success of these products will be key to long-term financial stability and reducing reliance on dilutive financing or high-cost debt.

Corporate Governance

Related Party Transactions

• The promissory note was issued to Keystone Capital Partners, LLC. While not explicitly stated as a related party, the repeated financing arrangements (ELOC, prior promissory notes) with the same entity could suggest a close relationship or a primary financing partner.

Stakeholder Impact

• **Shareholders**: Will see their number of shares reduced by a 1-for-85 ratio, but their percentage ownership (excluding fractional shares) will remain the same. Those with fractional shares will receive cash. The primary goal is to maintain Nasdaq listing, which benefits shareholders by preserving liquidity and market access.
• **Creditors**: The new promissory note is subordinate to existing senior debt (e.g., to Veru Inc.), which means senior creditors maintain their priority. The new lender, Keystone Capital Partners, LLC, holds an unsecured and subordinated position relative to senior debt.
• **Management/Employees**: Maintaining Nasdaq listing helps ensure the company's stability and access to capital, which indirectly supports employment and operational continuity.

Next Steps

• The company expects to file the Amendment to its Charter with the Secretary of State of the State of Delaware on June 11, 2025, to effect the reverse stock split.
• The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on June 13, 2025.
• The company's Common Stock will begin trading on a split-adjusted basis when the market opens on June 13, 2025, under a new CUSIP number, 68237Q203.
• The company will continue efforts to regain and maintain compliance with Nasdaq's minimum bid price requirement.
• The company will continue to seek proceeds from its Equity Line of Credit (ELOC) and potentially other securities offerings to repay the promissory note.

Key Dates

Recommendation

Keywords

Reverse Stock Split, Nasdaq Compliance, Promissory Note, Biotechnology, Mens Health, Oncology, Proclarix, ENTADFI, SEC Filing, Capital Raise, Corporate Governance